Cargando…
Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
Revefenacin is a novel once‐daily, lung‐selective, long‐acting muscarinic antagonist developed as a nebulized inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease. In a randomized, 4‐way crossover study, healthy subjects received a single inhaled dose of revefen...
Autores principales: | Borin, Marie T., Barnes, Chris N., Darpo, Borje, Pendyala, Srikanth, Xue, Hongqi, Bourdet, David L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004040/ https://www.ncbi.nlm.nih.gov/pubmed/31468714 http://dx.doi.org/10.1002/cpdd.732 |
Ejemplares similares
-
Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals
por: Darpo, Borje, et al.
Publicado: (2017) -
Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019) -
No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects
por: Mu, Song, et al.
Publicado: (2020) -
Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects
por: Darpo, Borje, et al.
Publicado: (2019) -
The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
por: Mueller, Markus S., et al.
Publicado: (2020)